Abstract
Resistance to first(1st), second(2nd) and third (3rd) generation of tyrosine kinase inhibitors(TKIs) in EGFR mutant NSCLC targeted therapies can be classified as either primary (i.e., intrinsic) or secondary (i.e., acquired). Primary resistance implies a de novo lack of response whereas secondary resistance refers to disease progression after a period of initial clinical benefit.Next generation sequencing(NGS) offers a comprehensive method of detecting these mechanisms to decide the next line of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
